Abbott Reports Five Year Results of Mitraclip Device for the Treatment of Mitral Regurgitation
Shots:
- The company highlighted 5yr. results from the (COAPT) trial evaluating MitraClip + guideline-directed medical therapy or guideline-directed medical therapy alone
- The results showed a significant reduction in the risk of annualized hospitalizations by nearly half (33% per year vs 57% in the control group), a reduction in risk of death (57% vs 67%), patients achieved durable MR reduction with 95% experienced reduced MR & showed a long-term benefit of the device
- The results showed minimally invasive mitral valve repair in advanced HF patients while MitraClip was safe and effective. The results were presented at the American College of Cardiology Scientific Sessions (ACC.23) and published in the NEJM
Ref: Abbott | Image: Abbott
Related Post:- Abbott Receives the US FDA and EU Approvals for Ablation Technologies to Treat Abnormal Heart Rhythms
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
